mani
viral
protein
undergo
proteolyt
process
event
requir
viru
infect
virion
assembl
issu
biochem
journal
strongin
cowork
report
proteas
west
nile
viru
unexpectedli
cleav
certain
substrat
pair
basic
residu
specif
resembl
furinlik
pc
proprotein
convertas
led
demonstr
furinpc
inhibitor
contain
poli
darginin
also
potent
inhibitor
anthrax
toxin
protect
antigen
myelin
basic
protein
potenti
substrat
structur
model
base
dengu
viru
provid
possibl
rational
observ
cleavag
specif
west
nile
viru
emerg
reemerg
infecti
diseas
direct
consequ
increas
air
travel
worldwid
intensif
farm
husbandri
global
warm
envelop
virus
eg
hiv
influenza
viru
sar
sever
acut
respiratori
syndrom
coronaviru
wnv
west
nile
viru
typic
contain
one
membranebound
glycoprotein
respons
viral
attach
membran
fusion
case
receptor
fusion
properti
contain
molecul
eg
influenza
viru
haemagglutinin
wherea
other
function
mediat
two
differ
glycoprotein
eg
member
alphaviru
famili
given
glycoprotein
often
also
major
viral
immunogen
structur
biochem
character
central
develop
vaccin
antivir
agent
sever
strategi
employ
develop
antivir
therapeut
commonli
use
approach
includ
inhibitor
enzym
involv
synthesi
viral
dnarna
molecul
includ
antibodi
receptor
analogu
block
viralhost
cell
interact
nlink
glycosyl
inhibitor
molecul
modul
viral
capsid
assemblydisassembl
inhibitor
viral
host
proteas
requir
matur
viral
proteinsglycoprotein
molecul
block
membran
fusion
despit
differ
replic
strategi
among
viru
famili
basic
principl
remain
similar
analog
mechan
govern
viru
entri
cell
use
enzym
direct
replic
viru
genom
envelop
glycoprotein
may
form
specif
pocketlik
site
interact
cellsurfac
receptor
progress
phase
adsorpt
virion
engulf
endocyt
vesicl
virion
fusion
domain
becom
activ
activ
accomplish
conform
chang
occur
acid
ph
andor
proteasespecif
cleavag
result
fusion
viral
hostcel
membran
penetr
host
cell
viral
membran
via
surfacespik
glycoprotein
fuse
either
plasma
endosom
membran
result
releas
viral
genom
cytosol
infect
cell
data
variou
infecti
virus
bacteri
toxin
shown
cleavag
surfacespik
glycoprotein
precursor
pathogen
one
member
pc
proprotein
convertas
famili
mammalian
subtilas
includ
basicaminoacidspecif
furin
pair
basic
amino
acid
convert
enzym
andor
kexin
isozym
site
proteas
requir
step
acquisit
fusiogen
potenti
thu
infecti
andor
cellcel
spread
capac
recent
crystal
model
catalyt
subunit
basicaminoacidspecif
pc
open
new
avenu
ration
design
potent
pc
inhibitor
see
recent
cathepsin
b
andor
cathepsin
l
emerg
endosom
cystein
proteinas
capabl
cleav
henc
activ
surfac
glycoprotein
number
infecti
virus
includ
ebola
sarscov
nipah
hendra
virus
inde
inhibitor
catbcatl
diminish
multipl
infecti
virus
cultur
cell
suggest
cleavag
specif
set
proteinas
gener
requir
exposur
fusiogen
sequenc
cell
surfac
acid
compart
endosom
emerg
zoonot
diseas
seiz
headlin
paper
around
world
emphas
import
prepared
face
current
outbreak
prevent
futur
outbreak
diseas
influenza
sar
ebola
wnv
surveil
research
laboratori
capac
effect
public
health
system
key
factor
control
pathogen
wnv
arboviru
member
famili
flavivirida
transmit
mosquito
bite
caus
epidem
febril
ill
mening
enceph
limb
weak
result
paralysi
death
vaccin
enzym
inhibitor
current
avail
use
antiflaviviru
therapi
spheric
envelop
capsid
wnv
diamet
approx
nm
contain
posit
singlestrand
rna
encod
c
capsid
e
envelop
prm
premembran
protein
well
seven
nonstructur
protein
probabl
contribut
viral
replic
kb
rna
translat
polyprotein
precursor
compris
three
structur
protein
c
e
preced
nonstructur
protein
believ
hostcel
proteas
includ
pc
furinlik
viral
encod
trypsinlik
serin
proteinas
respons
process
polyprotein
result
new
infecti
virion
hostcel
pclike
subtilas
activ
fusiogen
sequenc
cleavag
within
prm
predict
arghisserargargserargarg
site
activ
thought
process
polyprotein
three
junction
involv
trypticlik
cleavag
post
basic
residu
sinc
cleavag
vital
viru
suggest
inhibit
andor
hostcel
furinpclik
enzym
may
repres
power
antivir
strategi
paper
shiryaev
et
al
publish
issu
biochem
journal
aim
investig
catalyt
properti
wnv
identifi
potent
inhibitor
author
chose
first
produc
bacteri
cultur
chimaer
protein
compos
ntermin
locat
amino
acid
repres
central
domain
attach
via
ggggsgggg
linker
ctermin
affin
purif
tag
data
reveal
construct
autocatalyt
remov
ntermin
segment
sequenc
cleavag
glutyrlysli
result
fragment
remain
noncoval
complex
activ
remain
rigor
proven
whether
inde
fragment
requir
stabil
andor
activ
proteinas
vitro
homolog
proteas
wnv
propos
process
primarili
pair
basic
amino
acid
occupi
posit
inde
purifi
found
cleav
anthrax
toxinprotect
antigen
wherea
furinpclik
pentapeptid
fluorogen
substrat
pyrrtkrmca
pyrogluargthrlysarg
process
approx
better
cathepsin
blike
dipeptid
substrat
z
benzyloxycarbonyl
argargmca
view
pairedbasicaminoacid
cleavag
specif
author
investig
potenti
polydargininebas
peptid
potent
inhibitor
basicaminoacidspecif
pc
inhibitor
data
show
dodecam
dodecadarginin
amid
nonam
nonadarginin
amid
approx
better
inhibitor
k
approx
nm
respect
trypsin
inhibitor
aprotinin
k
nm
interestingli
nonadarginin
seem
approx
superior
inhibitor
hexam
hexadarginin
wherea
approx
better
furin
suggest
line
catalyt
pocket
may
contain
less
neg
charg
residu
aspart
andor
glutam
furin
use
predict
model
base
known
structur
homolog
dengu
viru
proteinas
author
suggest
line
catalyt
groov
wnv
latter
interact
posit
charg
residu
substrat
inhibitor
hypothesi
await
futur
experiment
proof
exampl
mutagenesi
crystallograph
analysi
nevertheless
present
data
suggest
furinpclik
inhibitor
could
use
inhibit
wnv
infect
inde
may
act
furin
level
need
viral
matur
via
proteinas
andor
infect
spread
via
glycoprotein
prm
measur
titr
wnvinfect
cell
treat
inhibitor
may
support
use
molecul
lead
compound
novel
antivir
knowledg
specif
led
author
use
pop
substrat
predict
program
http
popscssemonasheduau
use
human
proteom
databas
led
identifi
number
potenti
cytosol
substrat
includ
mbp
myelin
basic
protein
myelin
protein
zero
requir
neuron
function
neural
degener
associ
absenc
interestingli
data
present
show
approx
kda
mbp
process
approx
kda
product
result
cleavag
predict
glyalaprolysarg
site
although
proof
exact
site
ntermin
analysi
approx
kda
product
still
need
consist
inhibitor
profil
mbp
cleavag
block
dodecam
dodecadarginin
amid
aprotinin
work
shiryaev
et
al
open
new
avenu
toward
design
select
potent
inhibitor
could
find
applic
wnv
antivir
agent
howev
ravag
caus
viru
expect
extens
futur
studi
defin
multipl
hostcel
cytosol
protein
cleav
although
propos
neural
mbp
substrat
relev
also
clear
substrat
yet
discov
inde
recent
demonstr
wnv
alon
trigger
apoptosi
involv
issu
cognat
cytosol
substrat
implic
cell
death
pathway
remain
import
open
question
futur
studi
aim
identifi
ration
specif
potent
inhibitor
defin
detail
specif
wnv
rel
import
posit
well
p
posit
possibl
guid
threedimension
structur
wnv
vast
array
product
propos
medicin
chemistri
proteinas
deriv
hcv
hepat
c
viru
dengu
infecti
virus
sinc
discoveri
wnv
west
nile
district
uganda
took
year
begin
identifi
potent
inhibitor
hope
effort
lead
isol
smallmolecul
inhibitor
wnv
effect
lower
viral
burden
could
find
way
clinic
impress
reduct
hcv
rna
plasma
level
observ
inhibitor
clinic
trial
clearli
illustr
potenti
viral
enzymetarget
drug
discoveri
approach
spread
viru
sinc
necessit
vigil
well
continu
sustain
followup
bird
anim
die
result
wnv
infect
hope
scienc
structur
analysi
medicin
identif
potent
inhibitor
proteinas
help
allevi
pain
suffer
patient
infect
neurotrop
pathogen
end
surveil
effort
well
antivir
vaccin
approach
need
order
effect
curtail
